AAAAAA

   
Results: 1-21 |
Results: 21
Cyclin D1 overexpression in multiple myeloma - A morphologic, immunohistochemical, and in situ hybridization study of 71 paraffin-embedded bone marrow biopsy specimens
Authors: Athanasiou, E Kaloutsi, V Kotoula, V Hytiroglou, P Kostopoulos, I Zervas, C Kalogiannidis, PT Fassas, A Christakis, JI Papadimitriou, CS
Citation: E. Athanasiou et al., Cyclin D1 overexpression in multiple myeloma - A morphologic, immunohistochemical, and in situ hybridization study of 71 paraffin-embedded bone marrow biopsy specimens, AM J CLIN P, 116(4), 2001, pp. 535-542
Pulmonary toxicity syndrome following CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) chemotherapy
Authors: Fassas, A Gojo, I Rapoport, A Cottler-Fox, M Meisenberg, B Papadimitriou, JC Tricot, G
Citation: A. Fassas et al., Pulmonary toxicity syndrome following CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) chemotherapy, BONE MAR TR, 28(4), 2001, pp. 399-403
Collection of hematopoietic stem cells from patients with autoimmune diseases
Authors: Burt, RK Fassas, A Snowden, JA van Laar, JM Kozak, T Wulffraat, NM Nash, RA Dunbar, CE Arnold, R Prentice, G Bingham, S Marmont, AM McSweeney, PA
Citation: Rk. Burt et al., Collection of hematopoietic stem cells from patients with autoimmune diseases, BONE MAR TR, 28(1), 2001, pp. 1-12
Results of high-dose treatment with autologous stem cell support in patients with multiple myeloma
Authors: Fassas, A Tricot, G
Citation: A. Fassas et G. Tricot, Results of high-dose treatment with autologous stem cell support in patients with multiple myeloma, SEM HEMATOL, 38(3), 2001, pp. 231-242
Thalidomide in the management of multiple myeloma
Authors: Barlogie, B Zangari, M Spencer, T Fassas, A Anaissie, E Badros, A Cromer, J Tricot, G
Citation: B. Barlogie et al., Thalidomide in the management of multiple myeloma, SEM HEMATOL, 38(3), 2001, pp. 250-259
Results of autologous stem cell transplant in multiple myeloma patients with renal failure
Authors: Badros, A Barlogie, B Siegel, E Roberts, J Langmaid, C Zangari, M Desikan, R Shaver, MJ Fassas, A McConnell, S Muwalla, F Barri, Y Anaissie, E Munshi, N Tricot, G
Citation: A. Badros et al., Results of autologous stem cell transplant in multiple myeloma patients with renal failure, BR J HAEM, 114(4), 2001, pp. 822-829
Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years
Authors: Badros, A Barlogie, B Siegel, E Morris, C Desikan, R Zangari, M Fassas, A Anaissie, E Munshi, N Tricot, G
Citation: A. Badros et al., Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years, BR J HAEM, 114(3), 2001, pp. 600-607
Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone
Authors: Desikan, KR Tricot, G Munshi, NC Anaissie, E Spoon, D Fassas, A Toor, A Zangari, M Badros, A Morris, C Vesole, DH Siegel, D Jagannath, S Barlogie, B
Citation: Kr. Desikan et al., Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone, BR J HAEM, 112(1), 2001, pp. 242-247
High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions (vol 97, pg 2574, 2001)
Authors: Badros, A Barlogie, B Morris, C Desikan, R Martin, SR Munshi, N Zangari, M Mehta, J Toor, A CottlerFox, M Fassas, A Aniassie, E Schichman, S Tricot, G
Citation: A. Badros et al., High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions (vol 97, pg 2574, 2001), BLOOD, 98(2), 2001, pp. 271-271
High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions
Authors: Badros, A Barlogie, B Morris, C Desikan, R Martin, SR Munshi, N Zangari, M Toor, A Cottler-Fox, M Fassas, A Aniassie, E Schichman, S Tricot, G
Citation: A. Badros et al., High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions, BLOOD, 97(9), 2001, pp. 2574-2579
Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: a consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation
Authors: Comi, G Kappos, L Clanet, M Ebers, G Fassas, A Fazekas, F Filippi, M Hartung, HP Hertenstein, B Karussis, D Martino, G Tyndall, A van der Meche, FGA
Citation: G. Comi et al., Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: a consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation, J NEUROL, 247(5), 2000, pp. 376-382
Autologous stem cell transplantation in progressive multiple sclerosis - An interim analysis of efficacy
Authors: Fassas, A Anagnostopoulos, A Kazis, A Kapinas, K Sakellari, I Kimiskidis, V Smias, C Eleftheriadis, N Tsimourtou, V
Citation: A. Fassas et al., Autologous stem cell transplantation in progressive multiple sclerosis - An interim analysis of efficacy, J CLIN IMM, 20(1), 2000, pp. 24-30
Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone
Authors: Desikan, KR Tricot, G Dhodapkar, M Fassas, A Siegel, D Vesole, DH Jagannath, S Singhal, S Mehta, J Spoon, D Anaissie, E Barlogie, B Munshi, N
Citation: Kr. Desikan et al., Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone, BONE MAR TR, 25(5), 2000, pp. 483-487
Itraconazole oral solution for primary prophylaxis of fungal infections inpatients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazoleand amphotericin B
Authors: Harousseau, JL Dekker, AW Stamatoullas-Bastard, A Fassas, A Linkesch, W Gouveia, J De Bock, R Rovira, M Seifert, WF Joosen, H Peeters, M De Beule, K
Citation: Jl. Harousseau et al., Itraconazole oral solution for primary prophylaxis of fungal infections inpatients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazoleand amphotericin B, ANTIM AG CH, 44(7), 2000, pp. 1887-1893
Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities
Authors: Desikan, R Barlogie, D Sawyer, J Ayers, D Tricot, G Badros, A Zangari, M Munshi, NC Anaissle, E Spoon, D Siegel, D Jagannath, S Vesole, D Epstein, J Shaughnessy, J Fassas, A Lim, S Roberson, P Crowley, J
Citation: R. Desikan et al., Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities, BLOOD, 95(12), 2000, pp. 4008-4010
Stem cell transplantation for multiple myeloma - 10 years later
Authors: Siegel, DS Lim, SH Tricot, G Desikan, KR Fassas, A Mehta, J Singhal, S Anaissie, E Jagannath, S Barlogie, B
Citation: Ds. Siegel et al., Stem cell transplantation for multiple myeloma - 10 years later, HEMATOPOIETIC STEM CELL TRANSPLANTION, 2000, pp. 499-516
Autologous haematopoietic stem cell transplants for autoimmune disease - feasibility and transplant-related mortality
Authors: Tyndall, A Fassas, A Passweg, J de Elvira, CR Attal, M Brooks, P Black, C Durez, P Finke, J Forman, S Fouillard, L Furst, D Holmes, JA Joske, D Jouet, JP Kotter, I Locatelli, F Prentice, HG Marmont, AM McSweeney, P Musso, M Peter, HH Snowden, JA Sullivan, K Tichelli, A Vavriec, J Wulffraat, NM Schmitz, N Gratwohl, A
Citation: A. Tyndall et al., Autologous haematopoietic stem cell transplants for autoimmune disease - feasibility and transplant-related mortality, BONE MAR TR, 24(7), 1999, pp. 729-734
Lymphomatoid granulomatosis following autologous stem cell transplantation
Authors: Fassas, A Jagannath, S Desikan, KR Shah, HR Shaver, R Waldron, J Munshi, NC Barlogie, B Tricot, G
Citation: A. Fassas et al., Lymphomatoid granulomatosis following autologous stem cell transplantation, BONE MAR TR, 23(1), 1999, pp. 79-81
High-dose therapy with autologous haemopoietic stem cell support for Waldenstrom's macroglobulinaemia
Authors: Desikan, R Dhodapkar, M Siegel, D Fassas, A Singh, J Singhal, S Mehta, J Vesole, D Tricot, G Jagannath, S Anaissie, E Barlogie, B Munshi, NC
Citation: R. Desikan et al., High-dose therapy with autologous haemopoietic stem cell support for Waldenstrom's macroglobulinaemia, BR J HAEM, 105(4), 1999, pp. 993-996
Age is not a prognostic variable with autotransplants for multiple myeloma
Authors: Siegel, DS Desikan, KR Mehta, J Singhal, S Fassas, A Munshi, N Anaissie, E Naucke, S Ayers, D Spoon, D Vesole, D Tricot, G Barlogie, B
Citation: Ds. Siegel et al., Age is not a prognostic variable with autotransplants for multiple myeloma, BLOOD, 93(1), 1999, pp. 51-54
Total therapy with tandem transplants for newly diagnosed multiple myeloma
Authors: Barlogie, B Jagannath, S Desikan, KR Mattox, S Vesole, D Siegel, D Tricot, G Munshi, N Fassas, A Singhal, S Mehta, J Anaissie, E Dhodapkar, D Naucke, S Cromer, J Sawyer, J Epstein, J Spoon, D Ayers, D Cheson, B Crowley, J
Citation: B. Barlogie et al., Total therapy with tandem transplants for newly diagnosed multiple myeloma, BLOOD, 93(1), 1999, pp. 55-65
Risultati: 1-21 |